Table 2. Impact of clinical and pathological characteristics on 5-year DFS and OS.
| Variable | All patients | All Failure (LR and/or DM) | 5-Years DFS Rate | X2 | P | 5-Year OS Rate | X2 | P | |
|---|---|---|---|---|---|---|---|---|---|
| No. cases | % | ||||||||
| All patients | 2051 | 883 | 43.1% | 55.1% | 62.0% | ||||
| Gender | |||||||||
| Male | 1144 | 502 | 43.9% | 54.1% | 0.065 | 0.800 | 62.0% | 2.963 | 0.085 |
| Female | 907 | 381 | 42.0% | 56.2% | 60.2% | ||||
| Age, year | |||||||||
| ≤60 | 1187 | 497 | 41.9% | 57.1% | 0.078 | 0.005 | 64.1% | 12.258 | <0.0001 |
| >60 | 864 | 386 | 44.7% | 52.1% | 57.1% | ||||
| Tumor location | |||||||||
| Colon | 635 | 270 | 42.5% | 56.7% | 0.100 | 0.751 | 62.9% | 0.609 | 0.435 |
| Rectum | 1416 | 613 | 43.3% | 54.2% | 60.5% | ||||
| Tumor size, diameter | |||||||||
| ≤5.0 cm | 1440 | 608 | 42.2% | 56.3% | 8.186 | 0.004 | 66.8% | 19.960 | <0.0001 |
| >5.0 cm | 611 | 275 | 45.0% | 52.2% | 56.0% | ||||
| Preoperative CEA levels | |||||||||
| <5.0 ng/ml | 1102 | 404 | 36.7% | 62.4% | 29.562 | <0.0001 | 68.9% | 61.925 | <0.0001 |
| ≥5.0 ng/ml | 704 | 363 | 51.6% | 45.3% | 51.2% | ||||
| Unknown | 245 | 116 | 47.3% | 49.5% | 53.9% | ||||
| pT category (7th) | |||||||||
| pT2 | 128 | 26 | 20.3% | 78.6% | 80.647 | <0.0001 | 82.8% | 61.982 | <0.0001 |
| pT3 | 642 | 226 | 35.2% | 63.5% | 68.5% | ||||
| pT4 | 1281 | 631 | 49.3% | 48.4% | 55.3% | ||||
| pN category (7th) | |||||||||
| pN1a | 533 | 149 | 28.0% | 71.5% | 210.812 | <0.0001 | 74.3% | 241.467 | <0.0001 |
| pN1b | 539 | 215 | 39.9% | 57.8% | 63.7% | ||||
| pN1c | 282 | 87 | 30.9% | 69.9% | 73.9% | ||||
| pN2a | 374 | 207 | 55.3% | 39.8% | 49.9% | ||||
| pN2b | 323 | 225 | 69.7% | 25.7% | 32.9% | ||||
| npN category | |||||||||
| pN1a | 526 | 141 | 26.8% | 72.4% | 243.677 | <0.0001 | 77.2% | 252.334 | <0.0001 |
| pN1b | 629 | 207 | 32.9% | 65.6% | 68.4% | ||||
| pN2a | 495 | 252 | 50.9% | 46.0% | 57.2% | ||||
| pN2b | 401 | 283 | 70.6% | 26.0% | 35.9% | ||||
| Venous/lymphatic invasion | |||||||||
| Yes | 230 | 151 | 65.7% | 28.1% | 82.275 | <0.0001 | 34.7% | 84.399 | <0.0001 |
| No | 1821 | 732 | 40.2% | 58.3% | 64.3% | ||||
| Differentiation grade | |||||||||
| Well | 208 | 56 | 26.9% | 71.8% | 77.730 | <0.0001 | 75.4% | 86.138 | <0.0001 |
| Moderately | 1507 | 627 | 41.6% | 56.6% | 63.1% | ||||
| Poorly | 336 | 200 | 59.5% | 37.4% | 42.6% | ||||
| Pathological category | |||||||||
| Tubular adenocarcinoma | 1885 | 799 | 42.4% | 55.7% | 12.542 | 0.002 | 62.5% | 32.689 | <0.0001 |
| Mucinous adenocarcinoma | 125 | 58 | 46.4% | 55.2% | 50.4% | ||||
| Ring cell cancer | 41 | 26 | 63.4% | 34.7% | 35.6% | ||||
| Histological type | |||||||||
| Protrude | 1250 | 496 | 39.7% | 58.9% | 32.074 | <0.0001 | 63.8% | 20.552 | <0.0001 |
| Ulcer | 638 | 298 | 46.7% | 50.9% | 58.7% | ||||
| Infiltrative | 163 | 89 | 54.6% | 41.0% | 50.3% | ||||
| Adjuvant therapy | |||||||||
| Yes | 1827 | 771 | 42.2% | 55.8% | 11.710 | 0.001 | 63.9% | 30.826 | <0.0001 |
| No | 224 | 112 | 50.0% | 50.4% | 51.7% | ||||
| LNR category | |||||||||
| LNR1 | 1270 | 412 | 32.4% | 66.7% | 222.124 | <0.0001 | 71.7% | 245.392 | <0.0001 |
| LNR2 | 442 | 245 | 55.4% | 41.0% | 53.4% | ||||
| LNR3 | 186 | 107 | 57.5% | 37.3% | 40.6% | ||||
| LNR4 | 153 | 119 | 77.8% | 16.6% | 20.3% | ||||
| nLNR category | |||||||||
| nLNR1 | 1105 | 339 | 30.7% | 68.3% | 300.214 | <0.0001 | 71.8% | 261.948 | <0.0001 |
| nLNR2 | 542 | 266 | 49.1% | 48.4% | 60.1% | ||||
| nLNR3 | 238 | 150 | 63.0% | 33.3% | 42.7% | ||||
| nLNR4 | 166 | 128 | 77.1% | 16.5% | 21.8% | ||||